Publications and Presentations of the Tuberculosis Trials Consortium
(as of 15 May 2014)

I. Publications

2014


2013


Kolwijck E, Friedrich SO, Karinja MN, van Ingen J, Warren RM, Diacon AH. Early stationary phase culture

2012


Kolwijck E, Friedrich SO, Karinja MN, van Ingen J, Warren RM, Diacon AH. Early stationary phase culture

2011


2010


Yamshchikov AV, Kurbatova EV, Kumari M, Blumberg HM, Ziegler TR, Ray SM, Tangpricha V. Vitamin D status


2009


2008

2007


2006


2005


2004

2003


2002


2001


1999


Selected Guideline Publications Influenced by TBTC Work


II. Presentations and Abstracts

2014


2013


Kolwijck E, Friedrich SO, Venter A, van Ingen J, Diacon AH. Effect of culture supernatant containing resuscitation-promoting factors on the growth of M. tuberculosis from sputum samples collected during antituberculosis treatment. European Society for Clinical Microbiology and Infectious Diseases, April 27-30, 2013, Berlin, Germany.


Dooley K and Bliven-Sizemore E. Population pharmacokinetics of pyrazinamide. Presented at the Clinical Pharmacology of TB Drugs meeting, Sept 2013

Dorman S. Determining The Optimal Dose Of Rifapentine For Treatment Of Tuberculosis: How High Is High?


Weiner M and MacKenzie W. Substudy to characterize rifapentine pharmacokinetic (PK) parameters in patients with TB. Pharmacokinetics and pharmacodynamics of rifapentine and rifampin. 6th International Workshop on Clinical Pharmacology of TB Drugs, Sept 2013

Weiner M and MacKenzie W. Substudy to characterize rifapentine pharmacokinetic (PK) parameters in patients with TB. Pharmacokinetics and pharmacodynamics of rifapentine and rifampin. Gates sponsored TB Modeling and Analysis Consortium meeting in Beijing, China

Weiner M and MacKenzie W. Substudy to characterize rifapentine pharmacokinetic (PK) parameters in patients with TB. Pharmacokinetics and pharmacodynamics of rifapentine and rifampin. CPTR meeting in Washington, DC - October, 2013

Dorman S and Goldberg S. Study 29X, Phase 2 clinical trial, is to compare tolerability and safety of arms containing escalating doses of rifapentine Presentation, INTER-TB, St. George's University, 25 October 2013

Dorman S and Goldberg S. Study 29X, Phase 2 clinical trial, is to compare tolerability and safety of arms containing escalating doses of rifapentine Presentation, International Union Against Tuberculosis and Lung Disease, November 2013

2012


Sterling TR, Benson CA, Shang N, Villarino ME, the AIDS Clinical Trials Group, and the Tuberculosis Trials Consortium. Tolerability among HIV-infected persons of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection: The PREVENT TB Study (TBTC Study 26/ACTG 5259). International AIDS Society, July 2012.


Sterling TR, Benson CA, Shang N, Villarino ME, the AIDS Clinical Trials Group, and the Tuberculosis Trials Consortium. Tolerability among HIV-infected persons of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection: The PREVENT TB Study (TBTC Study 26/ACTG 5259). IV Congreso Nacional de Gesida, Spain, November 2012.

2011


2010


2009


2008


2007


2006


2005


2004


2003


2002


2001


2000

A Vernon for the TB Trials Consortium. TBTC Study 22 (Rifapentine Trial): Preliminary Results in HIV-negative Patients. Invited presentation at Rifapentine Evening Symposium, Meeting of the European Region of the IUATLD, Budapest (Hungary), April 2000.

A Vernon for the TB Trials Consortium. TBTC Study 22 (Rifapentine Trial): Preliminary Results in HIV-negative


Burman W, for the Tuberculosis Trials Consortium. Should tuberculosis treatment be extended in selected patients? Data from TBTC Study 22 and review of previous studies (poster). 38th Annual IDSA Meeting. New Orleans LA, Sept 7-10, 2000


1999


Bock N, for the Tuberculosis Trials Consortium. Safety and tolerability of once-weekly rifapentine/isoniazid (INH) vs. twice-weekly rifampin/INH in the continuation phase therapy of pulmonary tuberculosis in HIV-negative adults in USPHS Study 22. Poster presentation, 30th IUATLD World Conference on Lung Health, Madrid (Spain), September 1999.
1998


1997


III. Manuscripts and Presentations/Abstracts submitted

A. Manuscripts
